Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2024
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) (TA750)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 December 2021
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2017
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC